United Therapeutics announced that the company’s Phase II/III DISTINCT trial evaluating Unituxin (dinutuximab) with irinotecan compared to irinotecan or topotecan alone in relapsed or refractory small cell lung cancer failed to meet the primary efficacy endpoint.